Baudax Bio Spikes On Positive Phase II Trial Results For BX1000

Baudax Bio, Inc. (BXRX) shares are surging more than 58 percent on Tuesday morning trade after the company announced positive results from the phase 2 double-blind, randomised trial for BX1000 for neuromuscular blockade in patients undergoing elective surgery.

Currently, shares are at $5.02, up 59.42 percent from the previous close of $3.15 on a volume of 29,113,498.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT